Pazopanib and taxane combinations for metastatic or recurrent soft tissue sarcoma: A retrospective case series.

Sarkissian, Sarmen; Fruehauf, John P.

doi:10.1200/jco.2016.34.15_suppl.e22528

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study conducted on the small number of patients with STS (n = 9) illustrated clear benefits for patients with STS in terms of PFS, clinical benefit rate (CBR), etc. when compared to the single-agent pazopanib activity shown in the PALETTE trial [ 47 ]. Importantly, the toxicity profile was also acceptable for this combination of therapy.…”

Section: Discussionmentioning

confidence: 99%

2-APCAs, the Novel Microtubule Targeting Agents Active against Distinct Cancer Cell Lines

et al. 2021

View full text Add to dashboard Cite

Microtubules are known as the most attractive molecular targets for anti-cancer drugs. However, the number of serious limitations of the microtubule targeting agents (MTAs) including poor bioavailability, adverse effects (e.g., systemic and neural toxicity), and acquired resistance after initiation of MTA-based therapy remain the driving forces to develop the novel therapeutic agents effectively targeting microtubules and exhibiting potent anti-tumor activities. Here, we report the discovery of 2-amino-pyrrole-carboxamides (2-APCAs), a novel class of MTA, which effectively inhibited the growth of the broad spectrum of cancer cell lines in vitro, including various types of breast, prostate, and non-small lung cancer (NSLC), soft tissue sarcomas (STS) (e.g., leio-, rhabdomyo-, and fibrosarcomas), osteosarcomas and gastrointestinal stromal tumors (GISTs). Importantly, 2-APCAs were also effective in cancer cell lines exhibiting resistance to certain chemotherapeutic agents, including MTAs and topoisomerase II inhibitors. The anti-proliferative effect of 2-APCAs was due to their ability to interfere with the polymerization of tubulin and thereby leading to the accumulation of tumor cells in the M-phase. As an outcome of the mitotic arrest, cancer cells underwent apoptotic cell death which was evidenced by increased expression of cleaved forms of the poly-ADP-ribose polymerase (PARP) and caspase-3 and the increased numbers of Annexin V-positive cells, as well. Among the compounds exhibiting the potent anti-cancer activities against the various cancer cell lines indicated above, 2-APCA-III was found the most active. Importantly, its cytotoxic activities correlated with its highest potency to interfere with the dynamics of tubulin polymerization and inducement of cell cycle arrest in the G2/M phase. Interestingly, the cytotoxic and tubulin polymerization activities of 2-APCAs correlated with the stability of the «tubulin—2-АРСА» complexes, illustrating the “tubulin-2-APCA-III” complex as the most stable. Molecular docking showed that the binding site for 2-АРСА-III is located in α tubulin by forming a hydrogen bond with Leu23. Of note, single-cell electrophoresis (Comet assay) data illustrated the low genotoxic activities of 2-APCAs when compared to certain anti-cancer chemotherapeutic agents. Taken together, our study describes the novel MTAs with potent anti-proliferative and pro-apoptotic activities, thereby illustrating them as a scaffold for the development of successful chemotherapeutic anti-cancer agent targeting microtubules.

show abstract

Section: Discussionmentioning

confidence: 99%

2-APCAs, the Novel Microtubule Targeting Agents Active against Distinct Cancer Cell Lines

et al. 2021

View full text Add to dashboard Cite

show abstract

Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new

Frezza

Stacchiotti

Gronchi

2017

BMC Med

View full text Add to dashboard Cite

For metastatic soft tissue sarcoma (STS) patients not eligible for surgery, systemic treatments, including standard chemotherapy and newer biological compounds, still play the most relevant role in the management of the disease. An anthracycline and alkylating agent combination has formed the cornerstone of chemotherapy in STS for more than 30 years, with its value over that of administration of anthracycline as a single agent still being debated. Efforts have been made to improve the activity and minimise the toxicity of the combination, as well as to explore the upfront efficacy of agents known to be active in sarcoma and to develop new biological compounds. Nevertheless, beyond the first line, evidence for medical treatment in STS is less robust and all the more driven by histology. Thus, the introduction of kinases and small molecule inhibitors in the treatment armamentarium for STS is a major achievement in this setting. Preliminary data on immunotherapy are also available and discussed in this review.

show abstract

Pazopanib and taxane combinations for metastatic or recurrent soft tissue sarcoma: A retrospective case series.

Cited by 2 publications

References 0 publications

2-APCAs, the Novel Microtubule Targeting Agents Active against Distinct Cancer Cell Lines

2-APCAs, the Novel Microtubule Targeting Agents Active against Distinct Cancer Cell Lines

Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new

Contact Info

Product

Resources

About